Heart failure mystery: 500 patients join hunt for better treatment
NCT ID NCT07642921
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 500 people with a type of heart failure called HFpEF, where the heart pumps normally but doesn't fill properly. Researchers will use heart ultrasounds, blood tests, and medical history to group patients into different subtypes. The goal is to better understand the condition and help doctors tailor treatments in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors classify HFpEF into specific subtypes, leading to more personalized and effective treatment plans for patients.
- What could go wrong
- This is an observational registry, not a treatment trial, so it won't directly test any new therapy. Results may not change practice immediately.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will consist of consecutive patients with HF (NYHA class II - IV), aged 18 years or older, able to give their written informed consent to participate to the registry. Each patient will be uniquely identified in the study by a combination of his/her site number and patient number. No name will be entered in the database. Once obtained approval from each Ethics Committee center, consecutive patients will be included, up to the achievement of the study size. Patients may also be enrolled retrospectively, provided they give their written informed consent during a follow-up visit. Enrollment will be performed during outpatient visits or at-discharge in patients hospitalized for HF. Outpatient's visits will be further classified as planned or unplanned visits for worsening HF symptoms. Patient data collected during the study will include demographics, medical history, vital signs, LVEF and main cardiac structure and function parameters, and laboratory assessments.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients ≥ 18 years old * Signed patient informed consent form (ICF) * Diagnosis of chronic (documented HF hospitalization in the last year) or acute decompensated HF shown by signs and symptoms of HF and LVEF \>50% and, according to guidelines and the universal definition of HF, elevated levels of natriuretic peptides (NT-proBNP ≥300 pg/ml in sinus rhythm or NTproBNP ≥600 pg/ml in atrial fibrillation), at the time of enrolment (10) * Echocardiographic evidence of increased estimated LV filling pressures according to current guidelines Exclusion Criteria: * Planned participation or participation in a clinical trial; * Life expectancy \< 1 year because of non-cardiac causes; * History of recent (6 months) infective, or inflammatory, autoimmune or neoplastic diseases. * Stage \>4 CKD (estimated glomerular filtration rate \[eGFR\] \< 15 ml/min/1.73m2), * Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischemia or newly developed ischemic ECG changes), coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA in past 3 months; * Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalization for exacerbation within 12 months; * Congenital heart disease. * Primary pulmonary hypertension * Moderate-to-severe degenerative (primary) valve disease * Cardiomyopathy based on muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), or known pericardial constriction; * Implantation of cardioverter defibrillator (ICD) within 3 months * Implanted cardiac resynchronization therapy (CRT) and/or stable RV pacing.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure with preserved ejection fraction (hfpef) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Team-Based care may cut hospital readmissions for a common heart failure
- Stomach suturing may lighten the load on failing hearts
- Can tiny heart vessel damage predict heart failure?
- Can a new pill ease the burden of heart failure with preserved pumping?
- Iron and folic acid: a simple pill that could ease anemia and heart symptoms?
- Iron showdown: IV vs. pills for heart failure fatigue